| AASLD

Shaoying Zhang, Dan Wan, Mengchen Zhu, Guihu Wang, Xurui Zhang, Na Huang, Jian Zhang, Chongyu Zhang, Qi Shang, Chen Zhang, Xi Liu, Fanfan Liang, Chunyan Zhang, Guangyao Kong, Jing Geng, Libo Yao, Shemin Lu, Yongyan Chen, Zongfang Li – 12 September 2022

The Organ Procurement and Transplantation Network hepatocellular carcinoma classification: Alignment with Liver Imaging Reporting and Data System, current gaps, and future direction

Read more about The Organ Procurement and Transplantation Network hepatocellular carcinoma classification: Alignment with Liver Imaging Reporting and Data System, current gaps, and future direction

Andrea S. Kierans, Victoria Chernyak, Mishal Mendiratta‐Lala, Claude B. Sirlin, Elizabeth M. Hecht, Kathryn J. Fowler – 12 September 2022 – The Organ Procurement and Transplantation Network (OPTN) updated its allocation policy for liver transplantation to align with the Liver Imaging Reporting and Data System (LI‐RADS) for the diagnosis of hepatocellular carcinoma (HCC).

Reply

Read more about Reply

Francesco Vizzutti, Ciro Celsa, Salvatore Battaglia, Roberto Miraglia, Marco Enea, Fabio Marra, Antonio Colecchia, Calogero Cammà, Filippo Schepis – 12 September 2022

Population‐based meta‐analysis and gene‐set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids

Read more about Population‐based meta‐analysis and gene‐set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids

Samuel K. Handelman, Yindra M. Puentes, Annapurna Kuppa, Yanhua Chen, Xiaomeng Du, Mary F. Feitosa, Nicholette D. Palmer, Elizabeth K. Speliotes – 12 September 2022 – Nonalcoholic fatty liver disease (NAFLD) is prevalent worldwide. NAFLD is associated with elevated serum triglycerides (TG), low‐density lipoprotein cholesterol (LDL), and reduced high‐density lipoprotein cholesterol (HDL). Both NAFLD and blood lipid levels are genetically influenced and may share a common genetic etiology.

Primary Sclerosing Cholangitis and Cholangiocarcinoma

Read more about Primary Sclerosing Cholangitis and Cholangiocarcinoma

AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.

Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma

Read more about Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma

Miran Kim, Kam Man Hui, Ming Shi, Nancy Reau, Costica Aloman – 11 September 2022 – Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) treatment to hepatocellular carcinoma (HCC) are effective tools to control tumor growth, prolong survival, palliate symptoms, and improve quality of life for patients with intermediate‐stage HCC.

c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Read more about c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis

Jack Leslie, Jill E. Hunter, Amy Collins, Amelia Rushton, Lauren G. Russell, Erik Ramon‐Gil, Maja Laszczewska, Misti McCain, Marco Y. W. Zaki, Amber Knox, Yixin Seow, Laura Sabater, Daniel Geh, Neil D. Perkins, Helen L. Reeves, Dina Tiniakos, Derek A. Mann, Fiona Oakley – 10 September 2022

Racial/ethnic differences in fibrosis prevalence and progression in biopsy‐proven steatosis: A focus on the Asian American population

Read more about Racial/ethnic differences in fibrosis prevalence and progression in biopsy‐proven steatosis: A focus on the Asian American population

Rebecca G. Kim, Janet N. Chu, Eric Vittinghoff, Jasmine Deng, Jewel N. Reaso, James P. Grenert, Mandana Khalili – 9 September 2022 – Fatty liver disease (FLD) is a leading cause of chronic liver disease (CLD) globally, and vulnerable populations are disproportionately affected. Prior studies have suggested racial/ethnic differences in FLD prevalence and severity; however, these studies often excluded Asian Americans.

Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study

Read more about Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study

Jin Ge, Jean C. Digitale, Mark J. Pletcher, Jennifer C. Lai, for the N3C Consortium – 9 September 2022

High reproducibility of spleen stiffness measurement by vibration‐controlled transient elastography with a spleen‐dedicated module

Read more about High reproducibility of spleen stiffness measurement by vibration‐controlled transient elastography with a spleen‐dedicated module

Cristina Rigamonti, Micol Giulia Cittone, Giulia Francesca Manfredi, Andrea Sorge, Riccardo Moia, Andrea Patriarca, Maria Francesca Donato, Gianluca Gaidano, Mario Pirisi, Mirella Fraquelli – 8 September 2022 – Spleen stiffness measurement (SSM) by vibration‐controlled transient elastography (VCTE) is a noninvasive technique for estimating portal hypertension in patients with chronic liver disease (CLD), with its reproducibility yet to be established and its feasibility still unknown beyond CLD.

Subscribe to